{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:01:30Z","timestamp":1784127690208,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1007\/s10147-007-0733-3","type":"journal-article","created":{"date-parts":[[2008,2,29]],"date-time":"2008-02-29T16:10:03Z","timestamp":1204301403000},"page":"66-70","source":"Crossref","is-referenced-by-count":112,"title":["Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer"],"prefix":"10.1007","volume":"13","author":[{"given":"Magnus","family":"Rizell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Cahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larsolof","family":"Hafstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Olausson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Lindn\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,2,29]]},"reference":[{"key":"733_CR1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1148\/radiol.2301030753","volume":"230","author":"J.M. Llovet","year":"2004","unstructured":"Llovet JM, Bruix J (2004) Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization (letter). Radiology 230: 300\u2013302","journal-title":"Radiology"},{"key":"733_CR2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/jlts.2001.24645","volume":"7","author":"P. Neuhaus","year":"2001","unstructured":"Neuhaus P, Klupp J, Langrehr J (2001) mTOR inhibitors: an overview. Liver Transpl 7:473\u2013484","journal-title":"Liver Transpl"},{"key":"733_CR3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/bbrc.1998.9118","volume":"249","author":"T. Ogawa","year":"1998","unstructured":"Ogawa T, Tokuda M, Tomizawa K, et al. (1998) Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteo-sarcoma (ROS 17\/2.8) cells. Biochem Biophys Res Commun 249:226\u2013230","journal-title":"Biochem Biophys Res Commun"},{"key":"733_CR4","first-page":"886","volume":"59","author":"H. Hosoi","year":"1999","unstructured":"Hosoi H, Dilling MB, Shikata T, et al. (1999) Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 59:886\u2013894","journal-title":"Cancer Res"},{"key":"733_CR5","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0041-1345(02)02899-3","volume":"34","author":"G. Schumacher","year":"2002","unstructured":"Schumacher G, Oidtmann M, Rosewicz S, et al. (2002) Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus, which promotes cell growth. Transplant Proc 34:1392\u20131393","journal-title":"Transplant Proc"},{"key":"733_CR6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3748\/wjg.v11.i10.1420","volume":"11","author":"G. Schumacher","year":"2005","unstructured":"Schumacher G, Oidtmann M, Rueggeberg A. (2005) Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 11:1420\u20131425","journal-title":"World J Gastroenterol"},{"key":"733_CR7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","volume":"110","author":"D.H. Kim","year":"2002","unstructured":"Kim DH, Sarbassov DD, Ali SM, et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163\u2013175","journal-title":"Cell"},{"key":"733_CR8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","volume":"8","author":"M. Guba","year":"2002","unstructured":"Guba M, von Breitenbuch P, Steinbauer M, et al. (2002) Rapamycin inhibits primary and metastatic tumour growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128\u2013135","journal-title":"Nat Med"},{"key":"733_CR9","first-page":"789","volume":"25","author":"M. Rizell","year":"2005","unstructured":"Rizell M, Lindner P (2005) Inhibition of mTOR suppresses experimental liver tumours. Anticancer Res 25:789\u2013793","journal-title":"Anticancer Res"},{"key":"733_CR10","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1038\/sj.onc.1209558","volume":"25","author":"T. Roskamps","year":"2006","unstructured":"Roskamps T (2006) Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25:3818\u20133822","journal-title":"Oncogene"},{"key":"733_CR11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1432-2277.2004.00026.x","volume":"18","author":"M. Guba","year":"2005","unstructured":"Guba M, Koehl GE, Neppl E, et al. (2005) Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 18:89\u201394","journal-title":"Transpl Int"},{"key":"733_CR12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","volume":"59","author":"D.N. Franz","year":"2006","unstructured":"Franz DN, Leonard J, Tudor C, et al. (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490\u2013498","journal-title":"Ann Neurol"},{"key":"733_CR13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P. Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"733_CR14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2006.01.026","volume":"42","author":"P. Therasse","year":"2006","unstructured":"Therasse P, Eisenhauer EA, Verweij J. (2006) RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42:1031\u20131039","journal-title":"Eur J Cancer"},{"key":"733_CR15","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2004.07.960","volume":"22","author":"M.J. Ratain","year":"2004","unstructured":"Ratain MJ, Eckhardt G. (2004) Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J Clin Oncol 22:4442\u20134445","journal-title":"J Clin Oncol"},{"key":"733_CR16","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 3.0 Published date June 10, 2003, Ncl, Rockville"},{"key":"733_CR17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/02841860510044610","volume":"44","author":"M. Rizell","year":"2005","unstructured":"Rizell M, Cahlin C, Friman S, et al.(2005) Impressive regression of primary liver cancer after treatment with sirolimus. Acta Oncol 44:496","journal-title":"Acta Oncol"},{"key":"733_CR18","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1172\/JCI27282","volume":"116","author":"X. Xu","year":"2006","unstructured":"Xu X, Kobayashi S, Qiao W, et al.(2006) Induction of intrahepatic cholangiocellular carcinom by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 116:1843\u20131852","journal-title":"J Clin Invest"},{"key":"733_CR19","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1158\/1078-0432.CCR-04-0941","volume":"10","author":"F. Sahin","year":"2004","unstructured":"Sahin F, Kannangai R, Adegbola O, et al. (2004) mTor and p70 s6 kinase expression in primary liver neoplasms. Clin Cancer Res 10:8421\u20138425","journal-title":"Clin Cancer Res"},{"key":"733_CR20","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0046-8177(98)90205-2","volume":"29","author":"T. Torimura","year":"1998","unstructured":"Torimura T, Sata M, Ueno T, et al. (1998) Increased expression of vascular endothelial growth factor is associated with tumour progression in hepatocellular carcinoma. Hum Pathol 29:986\u2013991","journal-title":"Hum Pathol"},{"key":"733_CR21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3748\/wjg.v10.i5.649","volume":"10","author":"T. E. Wang","year":"2004","unstructured":"Wang T E, Kao C R, Chen L T, et al. (2004) Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 10:649\u2013653","journal-title":"World J Gastroenterol"},{"key":"733_CR22","first-page":"412","volume":"2005ASCOAnnualM","author":"J. D. Schwartz","year":"2005","unstructured":"Schwartz J D, Schwartz M, Goldman D, et al. (2005) Bevacizumab in hepatocellular carcinoma (HCC) in patients without metastasis and without invasion of the portal vein. J Clin Oncol 2005 ASCO Annual Meeting Proceedings 23:412","journal-title":"J Clin Oncol"},{"key":"733_CR23","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/lt.20237","volume":"10","author":"N.M. Kneteman","year":"2004","unstructured":"Kneteman NM, Oberholzer J, Al Saghier M, et al. (2004) Sirolimusbased immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 10:1301\u20131311","journal-title":"Liver Transpl"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-007-0733-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-007-0733-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-007-0733-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T20:24:46Z","timestamp":1559161486000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-007-0733-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1007\/s10147-007-0733-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}